keyword
MENU ▼
Read by QxMD icon Read
search

prednisone long term effects

keyword
https://www.readbyqxmd.com/read/30552159/direct-acting-antivirals-in-hepatitis-c-virus-associated-diffuse-large-b-cell-lymphomas
#1
Michele Merli, Marco Frigeni, Laurent Alric, Carlo Visco, Caroline Besson, Lara Mannelli, Alice Di Rocco, Angela Ferrari, Lucia Farina, Mario Pirisi, Francesco Piazza, Véronique Loustaud-Ratti, Annalisa Arcari, Dario Marino, Antonello Sica, Maria Goldaniga, Chiara Rusconi, Massimo Gentile, Emanuele Cencini, Francesco Benanti, Maria Grazia Rumi, Virginia Valeria Ferretti, Paolo Grossi, Manuel Gotti, Roberta Sciarra, Maria Chiara Tisi, Isabel Cano, Valentina Zuccaro, Francesco Passamonti, Luca Arcaini
BACKGROUND: International guidelines suggest hepatitis C virus (HCV) eradication by direct-acting antivirals (DAAs) after first-line immunochemotherapy (I-CT) in patients with HCV-positive diffuse large B-cell lymphoma (DLBCL), although limited experiences substantiate this recommendation. Moreover, only a few data concerning concurrent administration of DAAs with I-CT have been reported. SUBJECTS, MATERIALS, AND METHODS: We analyzed hematological and virological outcome and survival of 47 consecutive patients with HCV-positive DLBCL treated at 23 Italian and French centers with DAAs either concurrently (concurrent cohort [ ConC ]: n = 9) or subsequently (sequential cohort [ SeqC ]: n = 38) to first-line I-CT (mainly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone [R-CHOP]-like)...
December 14, 2018: Oncologist
https://www.readbyqxmd.com/read/30528678/new-concepts-to-reduce-glucocorticoid-toxicity
#2
Rieke Alten, Max Mischkewitz
70 years after their first use, low-dose glucocorticoids are a common part of pharmacological rheumatoid arthritis treatment. This is due to their well-proven capacities in symptom severity and disease activity reduction, in particular when combined with a disease-modifying anti-rheumatic drug, such as methotrexate. Nevertheless, glucocorticoid administration, in long-term especially, is also seen critically because of its potential adverse conditions. In order to achieve a reduction in treatment-related adverse events, modern therapy regimes should take into consideration patients' risk factors and therefore be individual...
December 5, 2018: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/30502231/long-term-follow-up-of-children-and-young-adults-with-autoimmune-hepatitis-treated-with-cyclosporine
#3
Silvia Nastasio, Marco Sciveres, Lorenza Matarazzo, Cristina Malaventura, Francesco Cirillo, Silvia Riva, Giuseppe Maggiore
BACKGROUND: Cyclosporine (CSA) is an alternative treatment for autoimmune hepatitis (AIH), however, its unknown long-term safety and efficacy have limited its use. AIMS: Examine the long-term outcome of children and young adults with AIH treated with CSA for at least 4 years. METHODS: Twenty patients were included in this retrospective study: 15 with classical AIH and 5 with autoimmune hepatitis/autoimmune sclerosing cholangitis overlap syndrome (ASC)...
November 3, 2018: Digestive and Liver Disease
https://www.readbyqxmd.com/read/30501869/combination-of-hyper-cvad-with-ponatinib-as-first-line-therapy-for-patients-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukaemia-long-term-follow-up-of-a-single-centre-phase-2-study
#4
Elias Jabbour, Nicholas J Short, Farhad Ravandi, Xuelin Huang, Naval Daver, Courtney D DiNardo, Marina Konopleva, Naveen Pemmaraju, William Wierda, Guillermo Garcia-Manero, Koji Sasaki, Jorge Cortes, Rebecca Garris, Joseph D Khoury, Jeffrey Jorgensen, Nitin Jain, Joie Alvarez, Susan O'Brien, Hagop Kantarjian
BACKGROUND: The combination of chemotherapy and ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukaemia has the potential to be a new standard of care for the disease; however, long-term efficacy and safety data are needed. Our aim was to evaluate the long-term efficacy and safety of this regimen in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukaemia in this ongoing phase 2 trial. METHODS: In our single-centre, phase 2, single-arm trial in the USA, adult patients with previously untreated Philadelphia chromosome-positive acute lymphoblastic leukaemia were sequentially enrolled...
December 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30467205/first-line-therapy-in-chronic-lymphocytic-leukemia-a-swedish-nation-wide-real-world-study-on-1053-consecutive-patients-treated-between-2007-and-2013
#5
Sandra Eketorp Sylvan, Anna Asklid, Hemming Johansson, Jenny Klintman, Jenny Bjellvi, Staffan Tolvgård, Eva Kimby, Stefan Norin, Per-Ola Andersson, Claes Karlsson, Karin Karlsson, Birgitta Lauri, Mattias Mattsson, Anna Bergendahl Sandstedt, Maria Strandberg, Anders Österborg, Lotta Hansson
The aim of this study was to investigate long-term outcome following first line therapy in consecutive chronic lymphocytic leukemia patients in a well defined geographic area (Sweden). All patients diagnosed with chronic lymphocytic leukemia (2007-2013) (n=3672) were identified from national registries, screening of patient files identified all (100%) first line treated (n=1053) and for those, depth analysis was performed. Endpoints were overall response rate, progression-free survival, overall survival and safety...
November 22, 2018: Haematologica
https://www.readbyqxmd.com/read/30458860/long-term-follow-up-of-autologous-hematopoietic-stem-cell-transplantation-for-refractory-juvenile-dermatomyositis-a-case-series-study
#6
Jia Zhu, Gaixiu Su, Jianming Lai, Boya Dong, Min Kang, Shengnan Li, Zhixuan Zhou, Fengqi Wu
OBJECTIVE: To follow up the refractory juvenile dermatomyositis (JDM) with autologous hematopoietic stem cell transplantation (AHSCT) in a long time and to investigate whether AHSCT is effective and safe to treat refractory JDM. METHODS: We collected the AHSCT and follow-up data of three patients with refractory JDM who received autologous peripheral blood CD34+ cell transplantation in our hospital between June 2004 and July 2015. Those data include: hight, weight, routine blood and urine tests, ESR, CK, ALT, AST, LDH, renal functional tests, lymphocyte subpopulations, HRCT and muscle MRI...
November 20, 2018: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/30451720/neutropenia-in-glycogen-storage-disease-ib-outcomes-for-patients-treated-with-granulocyte-colony-stimulating-factor
#7
David C Dale, Audrey Anna Bolyard, Tracy Marrero, Merideth L Kelley, Vahagn Makaryan, Emily Tran, Jamie Leung, Laurence A Boxer, Priya S Kishnani, Stephanie Austin, Corbinian Wanner, Iris A Ferrecchia, Dina Khalaf, Dawn Maze, Joanne Kurtzberg, Cornelia Zeidler, Karl Welte, David A Weinstein
PURPOSE OF REVIEW: Glycogen storage disease Ib (GSD Ib) is characterized by hepatomegaly, hypoglycemia, neutropenia, enterocolitis and recurrent bacterial infections. It is attributable to mutations in G6PT1, the gene for the glucose-6-phosphate transporter responsible for transport of glucose into the endoplasmic reticulum. Neutropenia in GSD Ib is now frequently treated with granulocyte colony-stimulating factor (G-CSF). We formed a cooperative group to review outcomes of the long-term treatment of GSD Ib patients treated with G-CSF...
January 2019: Current Opinion in Hematology
https://www.readbyqxmd.com/read/30409719/modified-vr-cap-alternating-with-rituximab-and-high-dose-cytarabine-an-effective-pre-transplant-induction-regimen-for-mantle-cell-lymphoma
#8
Stephen D Smith, Shruti Gandhy, Ajay K Gopal, Prathima Reddy, Mazyar Shadman, Brian G Till, Ryan C Lynch, Sandra Kanan, Andrew Cowan, Lauren Low, Brian T Hill
BACKGROUND: Initial treatment of mantle cell lymphoma (MCL) incorporating autologous stem cell transplantation affords long-term remissions, but relapses still occur. Optimal pretransplant therapy will afford high complete response rates and not impair stem cell collection. Incorporation of bortezomib represents a natural evolution of pretransplant therapy, given its proven first-line efficacy and minimal impact on stem cell collection. PATIENTS AND METHODS: At the University of Washington/Seattle Cancer Care Alliance and the Cleveland Clinic Foundation, we developed modified VR-CAP/R+ara-C (bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone, alternating with rituximab and high-dose cytarabine), for transplant-eligible patients with MCL...
October 17, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/30350359/tetracycline-nicotinamide-and-lesionally-administered-clobetasol-as-a-therapeutic-option-to-prednisone-in-patients-with-bullous-pemphigoid-a-comparative-retrospective-analysis-of-106-patients-with-long-term-follow-up
#9
Agnieszka Kalinska-Bienias, Emilia Kowalczyk, Pawel Jagielski, Cezary Kowalewski, Katarzyna Wozniak
BACKGROUND: Bullous pemphigoid (BP) is an autoimmune blistering disease associated with preexisting comorbidities and higher mortality. The interest in using therapy other than oral steroids in BP management results from severe complications and increased risk of death. The efficacy of oral doxycycline or whole-body application of topical clobetasol has been proven in randomized controlled trials. The case series study suggested that combination of tetracycline, nicotinamide, and lesionally administered clobetasol may also be useful...
October 22, 2018: International Journal of Dermatology
https://www.readbyqxmd.com/read/30345333/gender-differences-in-prednisone-adverse-effects-survey-result-from-the-mg-registry
#10
Ikjae Lee, Henry J Kaminski, Tarrant McPherson, Michelle Feese, Gary Cutter
Objective: Prednisone is a first-line immunosuppressive treatment for myasthenia gravis (MG), whereas short-term and long-term adverse effects (AEs) are a limiting factor in its usage. Method: The MG patient registry is a patient-driven, nation-wide database with patients of age ≥18 years, who were diagnosed with MG and live in the United States. Custom-designed "prednisone-steroid use and MG" survey was sent out to MG registry participants as part of semi-annual follow-up...
November 2018: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/30301458/syringomyelia-like-syndrome-in-neuromyelitis-optica-spectrum-disorder-complicated-with-sjogren-s-syndrome-a-case-report
#11
Xiangling Li, Zhengqi Lu, Yanqiang Wang
BACKGROUND: Besides CSF-flow obstruction, syringomyelia is associated with inflammatory spinal cord lesions. However, syringomyelia-like syndrome concomitant with neuromyelitis optica spectrum disorder (NMOSD) and primary Sjogren's syndrome (pSS) is extremely rare. Here, we would like to report a case of a patient with syringomyelia-like syndrome in NMOSD complicated with Sjogren's Syndrome. CASE PRESENTATION: A 64-old male Han Chinese, presented with three episodes of acute demyelinating processes in the central nervous system within 5 years...
October 9, 2018: BMC Neurology
https://www.readbyqxmd.com/read/30242442/diagnosis-and-clinical-course-of-three-adolescents-with-amiodarone-induced-hyperthyroidism
#12
Julia Gesing, Julia Hoppmann, Roman Gebauer, Roland Pfäffle, Astrid Bertsche, Wieland Kiess
Amiodarone-induced hyperthyroidism is a known side effect of amiodarone treatment. In the pediatric population, long-term amiodarone treatment is rarely indicated because of its severe side effects including thyroid function impairment. Treatment is therefore restricted to therapy-resistant arrhythmias. In the literature, scarce data are available on the management and therapy of amiodarone-induced thyroid dysfunction at a young age. We present three adolescent patients developing amiodarone-induced thyrotoxicosis in the months after amiodarone therapy...
December 2018: Pediatric Cardiology
https://www.readbyqxmd.com/read/30197508/glucocorticoid-induced-delayed-fracture-healing-and-impaired-bone-biomechanical-properties-in-mice
#13
Yan-Zhi Liu, Mohammed P Akhter, Xiang Gao, Xiao-Yan Wang, Xiao-Bei Wang, Gang Zhao, Xin Wei, Hao-Jun Wu, Hang Chen, Dong Wang, Liao Cui
Background: The objective of the study was to investigate the effects of glucocorticoid (GC) on the fracture healing process in a closed femur fracture mice model. Materials and methods: Forty 12-week-old female CD-1 mice were randomly allocated into four groups: healthy control and mice with prednisone exposure (oral gavage), 6 mg/kg/day (GC-L), 9 mg/kg/day (GC-M) and 12 mg/kg/day (GC-H). Three weeks after the initiation of prednisone dosing, closed femur fractures were created on prednisone-exposed mice and the healthy control...
2018: Clinical Interventions in Aging
https://www.readbyqxmd.com/read/30159547/alzheimer-s-disease-and-intranasal-fluticasone-propionate-in-the-fda-medwatch-adverse-events-database
#14
Steven Lehrer, Peter H Rheinstein
Background: Studies of Alzheimer's disease suggest that neuroinflammation or deranged brain wound healing may be a cause of some cases. But a placebo controlled study showed no effect at all on Alzheimer's disease of low dose oral prednisone after one year. Introducing the steroid directly into the hippocampus and rhinencephalon via the nose, as happens in hay fever subjects, could be more effective. Objective: In the present study, we analyzed FDA MedWatch data for intranasal fluticasone propionate (Flonase) to determine the frequency of Alzheimer's disease as an adverse event reported after use of the medication...
2018: JAD reports
https://www.readbyqxmd.com/read/30142801/bilateral-thalamic-and-mesencephalic-infarctions-with-hypopituitarism-as-long-term-complications-postradiotherapy-a-case-report
#15
Liang Hui, Hu Shijun, Liu Tao, Wen Guoqiang, Huang Shixiong
BACKGROUND: Radiation is widely used as the first-line treatment for nasopharyngeal carcinoma (NPC) and improves survival. Nevertheless, radiation also places the patients at risk of radiation-induced adverse effects, such as transient ischemic attack, ischemic stroke, hypopituitarism, and cranial nerve and temporal lobe dysfunction. CASE REPORT: A 54-year-old woman who had undergone radiation treatment for NPC 14 years earlier and had no cerebrovascular risk factors, visited our department 4 days after sudden onset of consciousness disturbance...
August 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/30135417/early-sirolimus-based-immunosuppression-is-safe-for-lung-transplantation-patients-retrospective-single-arm-exploratory-study
#16
Jacek Wojarski, Sławomir Żegleń, Marek Ochman, Wojtek Karolak
BACKGROUND Sirolimus, a mechanistic target of sirolimus inhibitor, is an immunosuppression medication for patients undergoing heart and abdominal transplantation. Sirolimus-based immunosuppression administered de novo post-lung transplantation is associated with bronchial anastomosis healing-related complications. We hypothesized that sirolimus administration within the first postoperative month in selected lung transplant recipients is safe and may be associated with favorable short-term and long-term outcomes due to its anti-proliferative properties and minimal adverse side effects...
August 23, 2018: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://www.readbyqxmd.com/read/30099821/switch-from-abiraterone-plus-prednisone-to-abiraterone-plus-dexamethasone-at-asymptomatic-psa-progression-in-patients-with-metastatic-castration-resistant-prostate-cancer
#17
Charlotte Fenioux, Christophe Louvet, Emilie Charton, Francois Rozet, Stanislas Ropert, Dominique Prapotnich, Eric Barret, Rafael Sanchez-Salas, Annick Mombet, Nathalie Cathala, Marie-Liesse Joulia, Jean-Luc Molitor, Julie Henriques, Franck Bonnetain, Xavier Cathelineau, Mostefa Bennamoun
OBJECTIVE: To evaluate the effects of switching from prednisone (P) to dexamethasone (D) at asymptomatic prostate-specific antigen (PSA) progression in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). MATERIALS AND METHODS: Among 93 patients treated with AA between January 2013 and April 2016 in our institution, 48 consecutive asymptomatic patients with mCRPC, who experienced biochemical progression on treatment with AA+P 10 mg/day, were included...
August 11, 2018: BJU International
https://www.readbyqxmd.com/read/30020020/medical-adherence-in-patients-with-systemic-lupus-erythematosus-in-germany-predictors-and-reasons-for-non-adherence-a-cross-sectional-analysis-of-the-lula-cohort
#18
G Chehab, G M Sauer, J G Richter, R Brinks, R Willers, R Fischer-Betz, B Winkler-Rohlfing, M Schneider
Objective Adherence to medication has a major impact on treatment control and success especially in chronic diseases but often remains unrecognized. Besides clinical, socioeconomic, disease-related and treatment-related parameters, general and personal health beliefs, as well as perception of health, can affect adherence. Our aim was to investigate the adherence to lupus-specific medications in German lupus patients and to assess influencing factors including detrimental or beneficial effects of health perceptions and beliefs...
September 2018: Lupus
https://www.readbyqxmd.com/read/30002799/successful-management-of-kaposiform-hemangioendothelioma-with-long-term-sirolimus-treatment-a-case-report-and-review-of-the-literature
#19
Matteo Chinello, Daniela Di Carlo, Francesca Olivieri, Rita Balter, Massimiliano De Bortoli, Virginia Vitale, Ada Zaccaron, Elisa Bonetti, Alice Parisi, Simone Cesaro
Background: Kaposiform Hemangioendothelioma (KHE) is a rare vascular tumour of the infancy and the first decade of life. It is locally aggressive and potentially life threatening when associated with consumptive coagulopathy, known as Kasabach-Merritt syndrome (KMS). No consensus or guideline for the therapy has been reached because of the lack of prospective trials, and the different standard care suggestions are based on retrospective case series. Case report: We report the case of a 9-month-old male with KHE and KMS in which the initial response, obtained with prednisone and vincristine, was subsequently consolidated and strengthened by long-term treatment with sirolimus, a mTOR inhibitor...
2018: Mediterranean Journal of Hematology and Infectious Diseases
https://www.readbyqxmd.com/read/29998211/long-term-treatment-with-infliximab-in-pediatric-vogt-koyanagi-harada-disease
#20
Gustavo A Budmann, Ludmila García Franco, Alejandra Pringe
Purpose: To report a case of pediatric Vogt-Koyanagi-Harada (VKH) successfully treated with infliximab and methotrexate for ten years. Observations: A 9-year-old Hispanic girl with VKH disease, was successfully treated with oral methotrexate 15 mg/week and oral prednisone 40 mg/day (1mg/kg/day). But when oral prednisone was tapered to 10 mg/day over a 3-month period, inflammation recurred. Patient was considered as corticosteroid-dependent thus infliximab 7mg/kg/pulse was started on days 0, 15, 60 and every 60 days thereafter...
September 2018: American Journal of Ophthalmology Case Reports
keyword
keyword
170864
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"